SPOTLIGHT: Investors yawn at Maraviroc endorsement

Investors largely shrugged off yesterday's unanimous vote by an FDA panel to back Pfizer's Maraviroc, a first-in-a-class drug for HIV. The therapy will be limited to a narrow share of the market as other HIV drugs with fewer side effects compete for the agency's approval. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.